The high TGF-β1, C5a diagnostic and Gliomedin levels together with clinical assessment could be used to personalize treatments in 92 % of Neuro-PASC patients with brain fog, fatigue, or both with existing TGF-β1 and C5a therapies and or therapies in late-stage development available for testing to determine the benefits. This evidence concerns the gene C5 and long COVID-19.